Manifold will use its tissue-targeting shuttle technology to help Roche develop new therapeutics for diseases of the central ...

Industry leaders say uncertainty in funding, clinical development and manufacturing is driving companies to embrace digital ...

Vinay Prasad, chief of the FDA’s Center for Biologics Evaluation and Research, is planning to publish a paper this month to ...

Pfizer insists that Novo Nordisk’s unsolicited offer to acquire Metsera is an effort from the Danish pharma to “suppress ...

George Tidmarsh, who helmed the FDA’s Center for Drug Evaluation and Research, resigned Sunday following a complaint by biopharma investor Kevin Tang, whose affiliated company, Aurinia Pharmaceuticals ...

There are a number of considerations that can help streamline the pathway to the clinic. One of the first is which vector system will be used, with AAV and lentivirus being two of the most commonly ...

Gilead is actively looking for late-stage and de-risked assets for potential deals across various therapeutic spaces, ...

Otsuka Pharmaceuticals could shell out over $400 million in total for the Asia-Pacific rights to 4D-150, which combines a ...

Novo Nordisk has submitted an unsolicited bid to buy obesity biotech Metsera out from under Pfizer, offering $6 billion ...

With a 100% response rate in a Phase II study, KYV-101 sets a new efficacy bar in generalized myasthenia gravis, according to ...

Late-breaking Phase III data show ianalumab, Novartis’ dual-targeted antibody, reduced disease activity and patient burden in ...

Bristol Myers Squibb beat analyst and consensus estimates for the third quarter with $12.2 billion in sales, but executives ...